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Prostate cancer is the most common cancer diagnosed in 
men. It is estimated that one in every seven men will be di-
agnosed with the disease during his lifetime. Although the 
medical community utilizes early diagnostic tools and new 
therapeutic approaches for localized disease, the National 
Institutes of Health’s Surveillance, Epidemiology, and End 
Results Program (SEER) estimates that 26,730 deaths will 
be attributed to metastatic prostate cancer in 2017. Molec-
ular hallmarks of prostate cancer include aberrant signal-
ing of the androgen receptor (AR) and phosphoinositide 
3-kinase (PI3K) pathways (Ferté et al., 2010; Perner et al., 
2015), as well as expression of prostate-specific membrane 
antigen (PSMA; Sweat et al., 1998). In fact, PSMA (also 
known as folate hydrolase 1 [FOLH1] or glutamate car-
boxypeptidase II [GCP II]; EC number 3.4.17.21; gene 
symbol FOLH1; gene ID 2346) is the most prominent pros-
tate cancer cell-surface biomarker and is also found in the 
neovasculature of solid tumors (Chang et al., 1999). PSMA 
(FOLH1, GCP II) is normally expressed in the proximal 
renal tubules and duodenum, where it plays a major role 
in the processing and uptake of dietary folates, and in the 
brain, where it processes N-acetyl-l-aspartyl-l-glutamate 
(NAAG) to modulate the output of glutamate signal-
ing transduced via the metabotropic glutamate receptor 
(mGluR) pathway (Rajasekaran et al., 2005; Rahn et al., 
2012a). PSMA has been successfully used for the imaging 
of primary and metastatic prostate cancer in patients with 
radiolabeled PSMA-targeting antibodies or, more recently, 
small molecules (Pandit-Taskar et al., 2015; Maurer et al., 
2016). PSMA-targeted radiotherapy in meta static castra-
tion-resistant prostate cancer was recently able to confer 
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improved biochemical and radiological response, with sus-
tained decline in prostate-specific antigen (PSA) levels and 
decreased lesion number and size (Kratochwil et al., 2016; 
Rahbar et al., 2017). In spite of the significant interest in 
PSMA as a target for imaging and therapy, the biological 
role of PSMA in prostate cancer remained elusive. Although 
previous studies showed that PSMA confers an advantage 
to prostate cancer cells through the processing of polyglu-
tamated folates to folic acid and additionally affects the 
expression of proinflammatory cytokines (Yao and Bacich, 
2006; Colombatti et al., 2009), an exact mechanism ex-
plaining a biological function of PSMA in prostate cancer 
was until now not known. In this work, we demonstrate 
that PSMA activates PI3K–Akt signaling in prostate cancer 
through release of glutamate as messenger molecule.
In addition to using PSMA as a structural anchor for 
targeted radiotherapeutics or experimental drugs (Hrkach 
et al., 2012), the primary clinical management of prostate 
cancer is currently based on therapeutic interventions that 
target the AR cascade, including androgen deprivation, an-
tiandrogens, and neoadjuvant chemotherapy (Mitsiades, 
2013). Unfortunately, patients almost always stop responding 
to AR inhibitors within 6 to 12 mo and progress to castra-
tion-resistant prostate cancer (Yuan et al., 2014). Genomic 
studies revealed that 40% of primary and 70% of metastatic 
prostate cancer patients have alterations in the PI3K signal-
ing axis, including loss of PTEN, which along with the AR 
support survival signals in the disease (El Sheikh et al., 2008; 
Reid et al., 2010; Taylor et al., 2010). Particularly, it was 
shown that PI3K signaling in prostate cancer depends pre-
dominantly on PI3K’s p110β isoform (Jia et al., 2008; Jiang 
et al., 2010). However, the mechanism of p110β activation 
in prostate cancer remained so far unknown (Schwartz et 
al., 2015). Efforts to elucidate this key mechanism demon-
strated p110β activation by a G protein–coupled receptor 
(GPCR; Cizmecioglu et al., 2016), but the exact GPCR 
remained unknown. In our work, we show that PSMA ac-
tivates a GPCR (mGluR I) through release of glutamate. 
Up-regulation of mGluR’s expression has been identified 
in several malignancies, including prostate cancer (Yu et al., 
2017). The findings of this study propose the use of PSMA 
as a surrogate marker for the activity of the PI3K signaling 
axis, which can be interrogated through molecular imaging 
with positron emission tomography (PET) imaging.
Combination therapies that block AR and PI3K path-
ways have been proposed. However, therapy with PI3K in-
hibitors in a disease-specific fashion has been challenging 
because of toxicity issues associated with off-tumor side ef-
fects from suppression of PI3K signaling in healthy organs 
(Dienstmann et al., 2014). In this work, we demonstrate that 
PSMA activates PI3K–Akt signaling in prostate cancer and 
demonstrate a new combination therapy in the inhibition 
of AR and PSMA as an alternative, tumor-selective strategy 
for PI3K signaling suppression to avoid PI3K inhibition in 
healthy tissues that lack PSMA expression.
rESuLtS
Expression of PSMA in patients with prostate cancer 
correlates with elevated mtor signaling
Because PSMA (FOLH1) has been identified as a promis-
ing marker for prostate cancer, we investigated whether its 
expression is reflective of disease state in cancer patients. We 
first analyzed genomic data obtained from prostate cancer pa-
tients with localized disease at our institution, and we found 
that higher PSMA expression was positively associated with 
faster biochemical recurrence (Fig.  1  A and Table S1) and 
metastasis (Fig. 1 B and Table S2). Given the clear correlation 
of PSMA with disease aggressiveness, we examined whether 
overexpression of PSMA correlates with alterations in major 
oncogenic signaling pathways. Immunohistochemical anal-
ysis of tissue microarray samples of prostate cancer patients 
showed that increased PSMA levels are indeed associated with 
the phosphorylation of 4EBP1, a downstream target of the 
mammalian target of rapamycin (mTOR; Fig. 1 C). Subse-
quent gene set enrichment analysis of patients’ genomics data 
further corroborated the histopathological findings, revealing 
that PSMA levels are associated with changes in the transcrip-
tional levels of mTOR-regulated genes (Fig. 1 D). Collec-
tively, these observations in clinical samples of prostate cancer 
prompted us to further elucidate a possible PSMA-induced 
signaling mechanism, which may provide novel personalized 
therapeutic interventions with improved disease management 
through PSMA-targeted PET imaging.
PSMA promotes downstream Akt signaling  
in prostate cancer
Intrigued by the clinical findings, we next examined whether 
PSMA expression in prostate cancer cell lines has any effect 
on the Akt–mTOR signaling cascade. To achieve this, we 
used human prostate cancer cell lines, which either expressed 
(LNCaP-Ctrl and PC3-PSMA) or lacked PSMA (LNCaP- 
KD and PC3-Ctrl; Fig. S1, A–C). Gene set enrichment analy-
sis revealed that in cells expressing PSMA, the levels of genes 
involved and regulated by Akt and mTOR were elevated 
(Fig. 2 A), similar to what was observed in patients, indicating 
that PSMA modulates the activity of the Akt–mTOR cas-
cade in prostate cancer.
Because the PSMA protein itself does not carry any sig-
naling-relevant moieties, we then focused on its enzymatic 
function as a glutamate carboxypeptidase. In the brain, PSMA 
modulates neuronal signaling within the synaptic cleft by 
hydrolyzing the amide bond that links the glutamate moi-
ety with N-acetylaspartate of the neurotransmitter NAAG. 
The released glutamate then activates postsynaptic metabo-
tropic glutamate receptors, leading to mobilization of cal-
cium within the postsynaptic neuron (Fig. 2 B). We reasoned 
that a similar mechanism might be at play in prostate cancer 
cells as well. Specifically, we examined whether similar to its 
function in the brain PSMA’s enzymatic release of glutamate 
could activate mGluR to facilitate activation of the PI3K–
Akt–mTOR axis. Because PSMA is known to hydrolyze folic 
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acids (Yao et al., 2008), we replaced NAAG for folic acid (vi-
tamin B9) as PSMA substrate, because vitamin B9 is ubiqui-
tous in the body. Toward this direction, we first confirmed the 
transcriptomic findings by assessing the phosphorylation lev-
els of Akt and its downstream targets. Indeed, we found that 
expression of PSMA increased the phosphorylation of Akt 
and its downstream targets S6K and 4EBP1, whereas ablation 
of PSMA expression had the opposite effect (Fig.  2, C–F). 
Inhibition of PSMA’s enzymatic activity with the highly se-
lective inhibitor 2-PMPA (Zhou et al., 2005; Ki = 275 pM) 
resulted in a decrease in phosphorylation (Fig. 2 G), which 
was comparable to suppression of PSMA expression. Hav-
ing demonstrated that PSMA activates Akt–mTOR signaling 
through its enzymatic activity, we next determined whether 
PSMA could be a bona fide modulator of oncogenic signal-
ing in prostate cancer. Therefore, we engineered PC3 cells 
to express enzymatically active PSMA (PC3-PSMAwt), and 
implanted them in male, athymic nude mice. Immunohisto-
chemistry on slices from mouse xenografts showed that ex-
pression of wild-type PSMA was associated with elevated Akt 
phosphorylation (Fig. 3 A and Fig. S1, D–G), which was in 
line with our in vitro studies and clinical findings. These data 
show that PSMA expression in prostate cancer up-regulates 
the Akt–mTOR signaling pathway and is mediated through 
PSMA’s enzymatic activity.
PSMA controls the phosphorylation of p110β,  
but not p110α or p110δ
As the PI3K-p110β isoform is particularly implicated in 
prostate cancer (Jia et al., 2008; Jiang et al., 2010), and be-
cause p110β is probably activated by a yet-unknown GPCR 
(Cizmecioglu et al., 2016), we hypothesized that glutamate 
released by PSMA may activate PI3K in an isoform-specific 
mode through the GPCRs of the mGluR I group. To test 
Figure 1. Expression of PSMA in patients is associated with activated Akt. (A and B) Elevated PSMA expression is associated with disease relapse (A) 
and metastases (B) in prostate cancer (MSK CC cohort PMID 25024180). High PSMA expression is defined as expression z-score >2, and low PSMA expres-
sion is defined as z-score ≤ 2. (C) Immunohistochemistry on representative samples from prostate cancer patients shows that enhanced PSMA expression 
correlates with elevated phosphorylation of the Akt target 4EBP1. (D) Gene set enrichment analysis comparing prostate cancer patients with normal PSMA 
levels with prostate cancer patients with high (z-score >2) PSMA levels. The dataset from the MSK CC prostate cancer cohort (PMID 25024180) was used.
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this, we used a clinically translational proteomics platform 
with high-throughput capabilities that utilizes as few as 25 
cells and examines the global phosphorylation status of the 
protein of interest through changes of the proteins isoelec-
tric point (NanoPro 1000; Protein Simple). We identified 
that inhibition of PSMA’s enzymatic activity impaired phos-
phorylation of PI3K-p110β, but not the p110α and p110δ 
isoforms (Fig. 3 B). Importantly, control treatment with an 
mGluR I agonist resulted in phosphorylation of p110β only 
similar to activation by PSMA in the presence of glutamated 
folate. Control studies corroborated that inhibition of p110β 
in prostate cancer decreased the phosphorylation of Akt 
(Fig. 3 C and Fig. S2 A), whereas glutamated folate did not 
alter the activation of Akt in cells lacking PSMA (Fig. S2 B).
Figure 2. Expression of enzymatically active PSMA up-regulates the Akt–mtor pathway. (A) PSMA-expressing cells are associated with enrichment 
of Akt and mTOR signaling signatures. Gene set enrichment analysis comparing PSMA-expressing cells (LNCaP-Ctrl) with their PSMA-negative counterparts 
(LNCaP-KD). The gene set data were derived from the mean of three independent experiments obtained through the Affymetrix platform. (B) In the brain, 
PSMA, encoded by the FOLH1 gene and termed glutamate carboxypeptidase II (GCP-II), modulates glutamatergic neurotransmission via activation of post-
synaptic metabotropic glutamate receptor (mGluR) system through the proteolytic cleavage of the amide bond of NAAG. (C–E) Increased phosphorylation 
of Akt, S6, and 4EBP1 in PSMA-expressing cells was determined with immunoblot analysis. Relative intensities normalized to actin levels (n = 3). (F and G) 
Expression of enzymatically active PSMA leads to phosphorylation of Akt, mTOR, and S6, as determined through a reverse-phase protein array (R&D Sys-
tems, Inc.). Changes in phosphorylation calculated as deviations from the control cell line (LNCaP-Ctrl for the PSMA knockdown cells [LNCaP-KD], PC3-Ctrl 
for PC3-PSMA that overexpress PSMA, and LNCaP-Ctrl for LNCaP-Ctrl cells that were treated for 2 h with the PSMA inhibitor 2-PMPA; n = 4 per condition). 
Graphs show mean ± SEM. **, P < 0.01 (unpaired t test).
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To further confirm that PSMA specifically activates 
p110β in prostate cancer, we used an Akt-specific fluores-
cent substrate that emits at 700 nm once phosphorylated 
by Akt (Shen et al., 2013) and observed that inhibition of 
PSMA, mGluR I, or p110β equally suppressed Akt activa-
tion (Fig.  3  D). Through a reverse-phase protein array, we 
observed that inhibition of PSMA’s enzymatic activity in 
PSMA-expressing cells decreased Akt activation but had no 
effect in cells lacking PSMA (LNCaP-KD and PC3-Ctrl; 
Fig. 3 E). Next, in order to corroborate that it really is the 
enzymatic activity of PSMA that induces the signaling cas-
cade, we created cells that expressed enzymatically inactive 
PSMA (PC3-PSMAmut). In these cells glutamated folate did 
not induce activation of Akt or its downstream targets, such 
as PRAS40 (Fig. S2, C–E). We also determined that in pros-
tate cancer cells that have wild-type, functional PTEN and 
express PSMA (22Rv1), treatment with glutamate folate in-
duced activation of Akt, similar to PSMA-expressing cells that 
do not express PTEN (LNCaP; Fig. S2, F–K). Furthermore, 
inhibition of PSMA decreased the activity of the Akt-target 
epithelial nitric oxide synthase and increased that of the AR, 
as reflected in higher levels of the PSA (Fig. S2, L and M). 
Figure 3. PSMA up-regulates Akt through activation of PI3K-p110β via mGlur I. (A) Immunohistochemistry of PC3-Ctrl and PC3-PSMA tumors 
grown on male, athymic nude mice shows elevated Akt1 phosphorylation in the PSMA-expressing tumors. Representative images of slices fixed in paraffin 
and stained with anti–human PSMA, pan-Akt, and phospho-Akt1 antibodies (bars, 100 µm). (B) Global changes in the phosphorylation status of components 
of the PI3K pathway were determined with the NanoPro 1000 system (Protein Simple). NanoPro-based analysis of PI3K’s catalytic subunits in LNCaP-Ctrl 
cells following 2 h stimulation with monoglutamated folate (Glu-Fol) or an mGluR I agonist (L-Quisqualic acid; PSMA inhibitor: 2-PMPA) in basal medium 
deprived of serum, folate and glutamate, showing that PSMA facilitates the phosphorylation of PI3K-p110β though activation of mGluR I. Before stimula-
tion, the cells were starved for 24 h in basal medium. Phosphorylation alterations were calculated as the difference observed between the treatment group 
and unstimulated cells (n = 3 per condition). (C) Inhibition of PI3K-p110β suppresses Akt activation, similar to PSMA and mGluR I inhibition in prostate 
cancer. LNCaP-Ctrl cells were treated with Glu-Fol and inhibitors for 2 h. Phosphorylation was assessed through a reverse-phase protein array (n = 3 per 
treatment). (D) The fluorescent Akt-specific substrate LS456, whose fluorescence emission shifts from emission in the near-infrared range (λ = 800 nm) to 
the red sector of the visible light (λ = 700 nm) upon phosphorylation by the kinase, was used to assess Akt activation by PSMA. LNCaP-Ctrl cells were treated 
with Glu-Fol and pharmacological agents for 2 h, as described above for panel B of this figure (n = 12 per treatment). (E) Inhibition of PSMA’s enzymatic 
activity with 2-PMPA decreases Akt’s phosphorylation in PSMA-expressing cells. Cells were grown in complete medium and treated for 2 h with 2-PMPA. 
Control cells were treated with 1× PBS. Changes in Akt’s phosphorylation were determined with a reverse-phase protein array (n = 3 per treatment). Graphs 
show mean ± SEM. ns, not significant; *, P < 0.05; ***, P < 0.001; ****, P < 0.0001 (ordinary one-way ANO VA).
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This is in line with previous work that demonstrated that 
inhibition of PI3K releases inhibition of the AR, and vice 
versa (Carver et al., 2011). Because of the elevated activity 
of Akt and epithelial nitric oxide synthase, it is likely possi-
ble that the higher levels of Akt protein in PSMA-expressing 
tumors (Fig. 3 A and Fig. S1 E) might be due to nitric oxide 
up-regulating the transcription factor RUNX2, which regu-
lates expression of Akt, in a reciprocal feedback loop in pros-
tate cancer (Cohen-Solal et al., 2015; Nesbitt et al., 2016). 
Collectively, these data demonstrate that through its ability 
to hydrolyze glutamated folates, PSMA facilitates activation 
of PI3K-p110β and Akt via mGluR I, thus promoting on-
cogenic signaling in prostate cancer. Collectively, these data 
show that PSMA activates p110β through enzymatic release 
of glutamate from folic acid.
PSMA activates mGlur I through the release of glutamate
After showing that PSMA initiates p110β-dependent PI3K 
signaling via mGluR I as a result of its enzymatic release of glu-
tamate from glutamated folate, we further evaluated the conse-
quences of PSMA-mediated activation of the GPCR mGluR I. 
Outside the central nervous system, such as in the duodenum, 
PSMA similarly releases free glutamate from glutamated folates 
through its zinc metalloproteinase catalytic mechanism (Klusák 
et al., 2009). We therefore showed that exogenous supplemen-
tation of the culture medium with either free glutamate or 
glutamated folate and recombinant PSMA activated Akt in a 
p110β-specific mode in PSMA-negative cells (Fig. 4 A).
Because PSMA regulates calcium levels in the brain 
through the release of glutamate, we reasoned that PSMA 
could also regulate calcium-mediated signaling in prostate 
cancer. Hence, we examined whether PSMA’s processing of 
glutamated folates had an impact on phospholipase C activa-
tion and cytoplasmic calcium levels in prostate cancer. In line 
with our proposed mechanism, elevation of cytoplasmic cal-
cium was observed in PSMA-expressing cells in the presence 
of glutamated folates in a dose-dependent pattern (Fig. S3, 
A–C). Supplementation of PSMA-null cells with glutamated 
folate and recombinant PSMA caused calcium increase in 
the cytoplasm, which was inhibited in the presence of either 
2-PMPA or the mGluR I antagonist (Fig. 4 B).
In PSMA-expressing cells, treatment with an mGluR 
I antagonist, phospholipase C inhibitor, or 2-PMPA abro-
gated the PSMA-mediated calcium influx to the cytoplasm, 
whereas mGluR I agonists potentiated it (Fig. S3 D). These 
findings indicate that PSMA-triggered mGluR I activation 
also leads to phospholipase C activation and downstream 
activation of inositol trisphosphate receptors that release 
calcium from the endoplasmic reticulum to the cytoplasm. 
Because apart from mGluR I, calcium levels can be also 
modulated by NMDA and AMPA receptors, we treated 
PSMA-expressing cells with inhibitors of these receptors. We 
found that treatment with these compounds did not have any 
effect on calcium levels in the presence of glutamated folate 
(Fig. S3 E), demonstrating that mGluR I is activated by free 
glutamate released by PSMA at the plasma membrane of 
prostate cancer cells. Because treatment with an mGluR I ag-
onist caused calcium mobilization in cells lacking PSMA, this 
showed that the glutamatergic system was functional in these 
cells (Fig. S3 F). As cells expressing PSMA had also higher 
Figure 4. released glutamate from PSMA-processed glutamate folate activates mGlur I and up-regulates cytoplasmic calcium levels. (A) PSMA 
activates Akt in a p110b-dependent fashion, using glutamate as the molecular messenger. PC3-Ctrl cells grown on 96-well plates were supplemented with 
Glu-Fol, recombinant PSMA, and inhibitors for 2 h. The change in 700-nm fluorescence intensity emission of the Akt-specific substrate LS456 was calculated 
based on unstimulated cells (n = 12 per treatment). (B) The released glutamate by PSMA engages mGluR I, mobilizing calcium to the cytoplasm. PC3-Ctrl 
cells were incubated in basal medium deprived of serum, folate, and glutamate for 4 h at 37°C, 5% CO2 (mGluR I agonist: (S)-3,5,-DHPG; n = 8 per condi-
tion). Detection was achieved with the Fluo-4 Direct calcium kit. (C) Intracellular calcium levels upon stimulation of cells expressing wild-type (PSMAwt) and 
enzymatically inactive PSMA (PSMAmut). Changes in [Ca2+] were calculated with respect to nonstimulated PC3-PSMAwt or PC3-PSMAmut cells grown in basal 
RPMI medium, as mentioned above for panel B of this figure (mGluR I agonist: (S)-3,5,-DHPG; n = 8 per condition). Graphs show mean ± SEM. *, P < 0.05, 
***, P < 0.001; ****, P < 0.0001 (ordinary one-way ANO VA).
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total calcium content than cells lacking this enzyme (Fig. S3 
G), this indicates that prostate cancer may rapidly mobilize 
calcium from the endoplasmic reticulum to the cytoplasm for 
signal transduction. Inhibition of PSMA’s enzymatic activity 
decreased the levels of inositol trisphosphate (Fig. S3 H), 
demonstrating that PSMA may have first stimulated mGluR 
I at the plasma membrane via glutamate, which in turn trig-
gered phospholipase C to generate inositol trisphosphate that 
activated endoplasmic reticulum’s inositol trisphosphate re-
ceptors to release calcium to the cytosol. Indeed, activation 
of mGluR I and initiation of downstream cytoplasmic cal-
cium efflux is mediated by PSMA at the plasma membrane, 
where PSMA colocalized tightly with the two members that 
constitute the mGluR I family (mGluR1 and mGluR5; Fig. 
S3 I). Hence, in order to relay environmental and nutrient 
cues to intracellular oncogenic signals using calcium as sec-
ondary messenger, PSMA at the plasma membrane has to 
be enzymatically active, as expression of enzymatically in-
active PSMA (Ghosh and Heston, 2003) abolished calcium 
mobilization in the presence of glutamated folate, whereas 
mGluR I was still functional (Fig. 4 C and Fig. S3 J). Over-
all, these data show that PSMA uses glutamated folate as its 
substrate for the production of glutamate that will locally 
activate mGluR I, leading to downstream signaling that sup-
ports prostate cancer progression.
Inhibition of PSMA in vivo confers a therapeutic advantage
Having demonstrated that expression of PSMA in prostate 
cancer patients is associated with Akt activation and faster 
disease progression and that PSMA through its enzymatic 
activity activates the PI3K–Akt axis, we next evaluated 
whether targeting of PSMA could serve as potential phar-
macological treatment avenue. Given that new targeted ther-
apies are on the rise, we identified that PSMA inhibition 
improved the effect of PI3K and mTOR inhibitors in vitro 
(Fig. 5, A–D; and Fig. S4, A and B). Because the PSMA in-
hibitor 2-PMPA has been previously used in clinical studies 
as a neuroprotective agent for diseases like multiple sclerosis 
(Zhou et al., 2005; Rahn et al., 2012b), we used it to prime 
animals that had PSMA-expressing xenografts and observed 
reduced tumor volume and growth (Fig. 6, A–C; and Fig. S5, 
A–I). Importantly, dose escalation further decreased tumor 
growth in animals with PSMA-positive xenografts (Fig. 
S5 J), and ablation of PSMA expression impaired tumor 
growth (Fig. S5, K–M).
Because PSMA activates the PI3K pathway and the AR 
negatively regulates PI3K, we next asked whether concomi-
tant inhibition of the AR pathway and PSMA-mediated acti-
vation of PI3K could improve treatment of PSMA-expressing 
tumors. We found that animals treated with either the anti-
androgen enzalutamide or 2-PMPA had smaller tumors 
Figure 5. Inhibition of PSMA improves 
response to chemotherapy in vitro. (A–D) 
Inhibition of FOLH’s enzymatic activity and 
PI3K-p110β reduces the viability of PSMA- 
expressing prostate cancer cells. Cells were 
treated with PI3K inhibitors (Pan: BKM120; 
PI3Kα: BYL719; PI3Kβ: GSK2636771; [inhibitor] 
= 200 nM) and 2-PMPA (200 nM) for 48 h at 
37°C, 5% CO2 (n = 12 per treatment). Viability 
was determined with the Alamar blue assay. 
Graphs show means ± SEM. ns, not signifi-
cant; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 
(ordinary one-way ANO VA).
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than control animals (Fig. 6 D). However, marked regression 
was observed in animals that received the antiandrogen and 
PSMA inhibitor, where the volume of 9 out of 10 tumors 
decreased (0 out of 10 tumors regressed with enzalutamide 
alone, and 4 out of 10 tumors treated with 2-PMPA decreased; 
Fig.  6 D and Fig. S5 N, inset). Combination therapy with 
enzalutamide and an mGluR I antagonist indeed conferred 
a therapeutic benefit, although it was less effective because 
of the poor aqueous solubility and stability of the mGluR I 
antagonist (Fig. S5 N). We further confirmed that treatment 
with 2-PMPA did not affect the growth of xenografts lacking 
PSMA that were implanted in PSMA+/+ or PSMA−/− animals 
(Fig. S5, O and P), indicating that the inhibitor’s therapeutic 
effect is associated with inhibition of the enzymatic activity 
of tumor-expressed PSMA. Overall, these data further sug-
gest that inhibition of PSMA in vivo may confer a therapeu-
tic benefit, where by targeting the tumor’s PSMA, its PI3K 
signaling is suppressed and off-tumor–associated toxicities 
caused by PI3K signaling inhibition are averted.
PSMA expression in prostate cancer patients 
correlates with Akt activity
After showing that PSMA inhibition provides a therapy ben-
efit and that PSMA activates p110β-dependent Akt signaling, 
and because prior work has identified PSMA as a promising 
biomarker for prostate cancer, we investigated whether PSMA 
expression was associated with distinct molecular profiles in 
patients, allowing stratification toward personalized, precision 
Figure 6. Inhibition of PSMA’s enzymatic activity in vivo provides a treatment benefit. (A and B) Male, athymic nude mice with LNCaP-Ctrl xeno-
grafts on both of their flanks were treated daily with vehicle (1× PBS) or PSMA inhibitor (2-PMPA) administered i.v. immediately after implantation of 
the cells (n = 10 mice per cohort). Graphs show mean ± SEM. ****, P < 0.0001 (unpaired t test). Inset shows the day where the tumors were first detected 
(n = 10 mice per cohort). (C) Survival curves of mice bearing LNCaP-Ctrl xenografts on their flanks (n = 10 animals per cohort). The animals received daily 
i.v. treatment (vehicle: 1× PBS; PSMA inhibitor: 2-PMPA) during the course of the study (75 d after implantation; day 0, implantation day). p-value was 
determined using the Gehan–Breslow–Wilcoxon test. (D) Waterfall plot of animals having bilateral LNCaP-Ctrl xenografts on their flanks (n = 5 mice per 
group). Treatment was administered daily i.v. on day 24 after xenograft implantation (enzalutamide, 0.5 mg/kg; 2-PMPA, 20 mg/kg; Enz + 2-P, 0.5 mg/kg 
enzalutamide and 20 mg/kg 2-PMPA). The black arrowhead on the timelines of C and D indicates the day of xenograft implantation, the purple arrowhead 
the day treatment started, the purple line the length of treatment, and the continuous blue line that the treatment was daily.
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medicine. Therefore, we screened a tissue microarray consist-
ing of samples from 76 prostate cancer patients and found that 
expression of PSMA correlates with phosphorylation of the 
Akt target 4EBP1 (Fig. 7 A and Fig. S4, C–H). PTEN’s levels 
did not correlate with PSMA levels and 4EBP1 status (Fig. S4 
F). These findings prompted us to examine whether nonin-
vasive assessment of PSMA expression through PET imaging 
could predict Akt activation in patients and thus serve as a 
potential prognostic marker that guides therapy. We examined 
whether Akt phosphorylation is higher in patients with ele-
vated PSMA levels, determined noninvasively with PET and 
magnetic resonance imaging (MRI) and the PSMA-specific 
probe 68Ga-HBED-CC before prostatectomy (Eder et al., 
2012; Maurer et al., 2016). After prostatectomy, sections of the 
removed tumor underwent histopathological analysis, includ-
ing quantitative immunofluorescence microscopy for PSMA 
and phosphorylated Akt, in order to obtain global tumor mo-
lecular information and address disease heterogeneity issues 
(Fig. 7, B and C). Principal component analysis (PCA) iden-
tified that PSMA expression and tracer uptake more strongly 
correlated with Akt’s phosphorylation at S473 than other 
clinical indicators of prostate cancer, such as Gleason score 
and PSA (Fig.  7, D and E). Despite the variability among 
samples from each patient (which is common because of can-
cer’s heterogeneity), these findings show that PSMA-based 
PET imaging can serve as a predictor of the global activation 
status of the PI3K–Akt pathway in a prostatic lesion. Particu-
larly when grading nearly identical tumors, this will provide a 
new means of risk stratification for patients and help identify 
those patients that require more aggressive therapy.
dIScuSSIon
Patient stratification has long been sought for treatment opti-
mization of men with primary and metastatic prostate cancer. 
The carboxypeptidase PSMA, which is strongly expressed on 
prostate cancer, has been used increasingly as target to guide 
therapy and imaging agents to prostate cancer, yet its bio-
logical role in the disease remained elusive and unexplored. 
Using transcriptomics, proteomics, and imaging, we show for 
the first time that PSMA provides a signaling function by re-
leasing glutamate from folic acid (vitamin B9). The glutamate 
activates nearby metabotropic glutamate receptors. These 
GCPRs lead to activation of p110β and concomitantly nega-
tively regulate the AR pathway. Critical to signaling initiation 
is PSMA’s processing of glutamated substrates, which acti-
vate proximal mGluR I, reminiscent of the enzyme’s function 
within the synaptic clefts of the central nervous system. This 
indicates also that the vitamin B9 (folic acid) is a potential 
accelerator of prostate cancer, because it provides glutamate 
through PSMA. Importantly, a recent large study of almost 
15,000 men showed that individuals with higher blood folate 
levels were at greater risk of high-grade prostate cancer (Price 
et al., 2016), underscoring the importance of our work.
Previous studies have shown that Akt signaling in pros-
tate cancer is driven by the p110β isoform of PI3K by an 
unidentified GPCR (Jia et al., 2008). In line with this, it was 
demonstrated that inhibition of p110β confers a therapeutic 
advantage in vivo and that combination therapy with PI3K 
and AR inhibitors suppresses the reciprocal negative feedback 
loop between these two pivotal signaling axes in prostate can-
cer (Carver et al., 2011). However, to our knowledge, there 
have been no efforts to identify the mechanism by which 
a GPCR specifically activates p110β in animal models and 
prostate cancer patients. Prior work has shown that PSMA is 
overexpressed in prostatic neoplasias and that AR inhibition 
up-regulates PSMA levels (Evans et al., 2011). Additionally, 
PSMA was identified as a zinc metalloproteinase capable of 
processing glutamated folates, with the released folate pro-
viding a proliferative advantage to prostate cancer cells (Yao 
and Bacich, 2006; Klusák et al., 2009). Before these studies, 
the field of neuroscience provided evidence that the enzyme’s 
role in the central nervous system is to modulate excitatory 
signaling through the processing of NAAG with refined spa-
tiotemporal regulation. Different groups implied that the 
spatial regulation of PSMA at the plasma membrane might 
facilitate oncogenic signaling in prostate cancer, although the 
mechanism remained elusive (Rajasekaran et al., 2005; Co-
lombatti et al., 2009). Our findings bridge this significant gap 
in knowledge and experimentally show that PSMA colocal-
izes with mGluR I members on the plasma membrane of 
prostate cancer cells, providing a mechanistic link between 
PSMA and mGluR I as the participating GPCR that activates 
p110β signaling. The causality between PSMA enzymatic ac-
tivity and p110β-driven Akt signaling shown by our work 
provides an appealing justification for the β-isoform–specific 
induction of PI3K signaling in prostate cancer, irrespective 
of PTEN status, and establishes a central functional role of 
PSMA as a diagnostic and therapeutic target for the inhibition 
of GPCR-driven oncogenesis in cancer. Collectively, our data 
support the hypothesis that PSMA converts environmental 
signals, such as nutrient abundance, into proliferative signals 
that drive pro-oncogenic activities during prostate cancer.
Our findings have important clinical implications for 
prostate cancer patient treatment. Expression of PSMA cor-
relates with activation of the PI3K–Akt pathway in patients. 
Noninvasive PET imaging can interrogate PSMA in the tumor 
with agents that are already in advanced clinical trials in the 
United States and Europe. Considering that the levels of PSA 
are not an accurate predictor of disease status and that prostate 
cancer is not FDG avid, our work suggests that PSMA-based 
PET imaging not only demonstrates the presence of prostate 
cancer but also noninvasively diagnoses a patient’s underlying 
molecular signaling aberrations, providing improved patient 
stratification and better treatment. Because PSMA is expressed 
in the neovasculature of other solid tumors and many of these 
tumors coexpress members of the mGluR family (Ristau et 
al., 2014; Yu et al., 2017), our data argue that PSMA might 
additionally have similar function in the tumor neovasculature.
Lastly, the observation that PSMA activates the PI3K 
pathways and negatively regulates the AR pathway has sig-
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nificant clinical implications, because PSMA and mGluR I 
inhibitors could be used in tandem with antiandrogens, such 
as enzalutamide or abiraterone. Our work with preclinical 
inhibitors of mGluR I, such as NPS 2390, and the PSMA 
inhibitor 2-PMPA, which has been previously tested in the 
clinic, establish this combination therapy strategy in vitro and 
in vivo. Because prior work showed that the combination of 
inhibitors of the AR and PI3K is required to elicit therapeutic 
efficacy in prostate cancer (Carver et al., 2011), and that PI3K, 
Akt, or mTOR inhibitors have some limitations, including 
off-target effects caused by their constitutive expression in 
other organs, inhibition of PSMA can be an alternative ther-
apeutic venue. In addition to pharmacological treatment, the 
results of the present study may provide dietary guidelines for 
cancer patients, such as folate-fortified food like bread and 
pasta (or frequently as an additive in Chinese food in the 
United States), and multivitamin supplements might support 
the pro-cancer activity of PSMA. It may also be intriguing 
if future studies delineate the temporal dynamics among 
PSMA-facilitated calcium mobilization, PI3K–Akt activa-
tion, and AR inhibition, along with evaluation of the status 
of PKC isozymes that are regulated by the AR in prostate 
cancer (Tanaka et al., 2003; Gonzalez-Guerrico et al., 2005; 
Xiao et al., 2009; Shankar et al., 2016) and control the activity 
of protein phosphatase 2, which modulates Akt.
In summary, our results demonstrate that apart from 
being a biomarker of prostate cancer, PSMA carries a previ-
ously unknown critical functional role in disease progression, 
transmitting environmental cues stemming from nutrients to 
initiate an intricate intracellular signaling repertoire. Specif-
ically, through release of glutamate from glutamated folates, 
including vitamin B9, it activates the glutamatergic system, 
mobilizing calcium, activating PI3K (Fig. 7 F), and trigger-
ing a growth-prevailing cascade into the cell. As we have 
demonstrated, this provides new insights on disease dynam-
ics, including the reason for the prevailing p110β signaling 
in prostate cancer, and therapeutic approaches, considering 
that mGluR I is expressed in several cancers, including mel-
anoma, lung, and pancreatic, and PSMA is expressed on the 
neovasculature of solid tumors. It is also possible that PSMA 
may up-regulate AKT activity via the calcium-dependent ac-
tivation of mTORC2, which in turn can phosphorylate AKT 
(Huang et al., 2013; Josselyn and Frankland, 2013). This might 
suggest the presence of a positive feedback loop, which can 
be part of future investigational efforts. In conclusion, because 
several PSMA-specific imaging agents are entering the clinic 
and one in seven men will be diagnosed with prostate cancer, 




Monoglutamate folate was purchased from Sigma-Aldrich, 
whereas the tri- and pentaglutamate folates were obtained 
from Schircks Laboratories. The following chemicals were 
acquired from Tocris: 2-PMPA (PSMA inhibitor), (S)-3,5,-
DHPG (mGluR I agonist), l-quisqualic acid (mGluR I ag-
onist), L-AP3 (mGluR I antagonist), U73122 (phospholipase 
C inhibitor), IEM 1460 (AMP AR blocker), D-AP5 (NMDA 
receptor antagonist), and NPS 2390 (mGluR I antagonist). 
From Sigma-Aldrich, we also obtained N-acetyl-L-cysteine 
and dimethyl sulfoxide. We purchased the following com-
pounds from Selleck Chemicals: BKM120 (pan-PI3K in-
hibitor), BYL719 (PI3K-p110α inhibitor), GSK2636771 
(PI3K-p110β inhibitor), enzalutamide (AR antagonist), 
everolimus (mTOR inhibitor of FKBP12), AZD8055 
(ATP-competitive mTOR inhibitor), INK128 (mTORC1/2 
inhibitor), and XL184 (VEG FR2 inhibitor). All chemicals 
were stored and their solutions prepared according to the 
suppliers’ recommendations.
cell lines
The human prostate cancer cell lines LNCaP, 22Rv1, and 
PC3, as well as the murine Lewis lung carcinoma cell line 
Figure 7. Expression of PSMA in patients allows their stratification in distinct groups that reflect activation of the Akt/mtor pathway. 
(A) Clustering analysis of patient tissue microarray data formed three distinct clusters where elevated PSMA expression correlated with enhanced 4EBP1 
phosphorylation in cluster B, whereas decreased PSMA expression was associated with decreased 4EBP1 phosphorylation in cluster C. Cluster A underlines 
disease and sample heterogeneity, where mixed PSMA staining (sample with PSMA-positive and negative foci) was associated with either lack or low phos-
phorylation of 4EBP1. The expression of PTEN is displayed but was not considered in the clustering analysis. (B and C) PET/MRI of prostate cancer patients 
using the PSMA-specific probe 68Ga-HBED-CC, and immunofluorescence microscopy analysis of cancer tissue from patients obtained after prostatectomy. 
Twelve patients were imaged with PET/MRI, and tissue samples from multiple sites of the biopsy were screened. Representative images are shown, with the 
corresponding microscopy slides stained for PSMA, pAKTS473 (Cell Signaling), and Hoechst 33342 (bars, 50 µm). (D and E) Biplot representation suggests that 
PSMA expression is associated with Akt phosphorylation at residues S473 and T308 and that PSMA immunostaining and PSMA-based PET (SUV values) are 
both good indicators of Akt’s phosphorylation, as these parameters are closer to Akt in the two-dimensional space defined by the primary principal com-
ponents PC1 and PC2 than other clinical parameters. The open circles show the samples stained per patient and underlie sample variability caused by the 
heterogeneous nature of the disease. Biplots derived from PCA of patients imaged with PET/MR and their samples underwent histopathological analyses, 
including immunofluorescence microscopy for phosphorylation of Akt on residues S473 and T308. Gleason, Gleason score; SUVmean, mean standardized 
uptake value of PSMA tracer. (F) Schematic representation of the overall pathway involving PSMA and induction of tumor-supporting signaling based on 
our data. Free glutamate released from PSMA after processing of glutamate-containing substrates activates mGluR I receptors found on the plasma mem-
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LL2, were obtained from the American Type Culture Col-
lection. All cell lines were regularly tested for mycoplasma 
contamination and authenticated by DDC Medical through 
the STR profiling method. The stocks of the human pros-
tate cancer cells lines were grown in a humidified incubator 
at 37°C, 5% CO2 and supplemented with RPMI 1640 me-
dium (Gibco) that contained 10% fetal bovine serum (Gem-
ini Bio-products), glutamine ([Gln]fn = 3  mM), 1% Hepes 
buffer, and 1% penicillin/streptomycin. LL2 cells were grown 
in DMEM (Gibco) that contained 10% fetal bovine serum 
and 1% penicillin/streptomycin. To generate cells that lacked 
PSMA, we used LNCaP cells, which express PSMA, and the 
Platinum Select retroviral shRNA-mir platform (DU53991) 
from TransOMIC Technologies, Inc. to knock down the gene 
PSMA that encodes PSMA (gene ID 2346), following the 
supplier’s guidelines. Selection was done in the presence of 
puromycin, and confirmation of generation of cells lacking 
PSMA was achieved with immunoblot analysis, using an 
anti–human PSMA antibody (YPS MA-1; Abcam). Quan-
titative real-time PCR was performed by Memorial Sloan 
Kettering Cancer Center’s Integrative Genomics Operation 
using total RNA extracted with TRIzol (Invitrogen) from 
cells grown to confluence on Petri dishes, followed by reverse 
transcription to cDNA using the ProtoScript First Strand 
cDNA synthesis kit (New England Biolabs), qPCR with the 
CFX real-time PCR detection system (Bio-Rad), and primer 
sequences previously reported (Yates et al., 2012). Normal-
ization for PSMA expression was done with LNCaP-Ctrl 
PSMA expression serving as the calibrator for all samples, and 
expression of β actin served as an endogenous control. The 
enzymatically inactive PSMA mutant was generated accord-
ing to a prior study (Ghosh and Heston, 2003), and the ability 
of PSMA-expressing cells to process monoglutamated fo-
late, releasing free glutamate in the solution, was determined 
through Molecular Probes’ Amplex Red Glutamic Acid assay 
following the supplier’s protocol (Thermo Fisher Scientific).
Bioinformatics analyses
The GeneChip Human Genome U133A 2.0 array from 
Affymetrix, Inc. was used to determine gene expression lev-
els in cells expressing or lacking PSMA. Each cell line was 
analyzed in triplicate, after growth of cells to confluence on 
Petri dishes, supplemented with complete media. Before total 
RNA extraction with TRIzol, the cells were washed three 
times with warm 1× PBS. The preparation of the arrays’ sam-
ples and subsequent data analysis were done at MSK CC’s 
Integrative Genomics Operation and Bioinformatics Core. 
To categorize the most differentially affected genes, we de-
termined each gene’s function through the NCBI Gene data-
base. The microarray data of the screened PSMA-positive 
and PSMA-negative human prostate cancer cells have been 
deposited to the National Center for Biotechnology Infor-
mation’s Gene Expression Omnibus repository (accession no. 
GSE104419). For the bioinformatics analyses of data from 
prostate cancer patients, we used a dataset recently reported 
(Hieronymus et al., 2014). In brief, from this dataset’s initial 
cohort (n = 168, PMID 25024180), we used the localized 
cases of primary tumors that have not had any neoadjuvant 
treatment and matched normal samples of patients that un-
derwent prostatectomy at MSK CC, following institutional 
review board approval. For gene set enrichment analyses, we 
used the corresponding gene sets that met the p-value < 0.01, 
false discovery rate q < 0.2 significance thresholds across the 
examined cohorts and cell lines. Gene networks were deter-
mined and visualized through Cytoscape, based on the in-
tersection of enriched gene sets that meet the significance 
thresholds in the studied cohorts/cells. PSMA expression was 
binned as high z >2 expression versus not, and PSMA expres-
sion was identified as a prognostic for biochemical recurrence 
and metastasis even after correcting for the clinical Stephan-
son nomogram score, which combines other prognostic vari-
ables like Gleason score and margins, through multivariate 
Cox regression. PSMA’s association with outcome was ex-
amined through a multivariate regression model, which ef-
fectively corrects for the nomogram score, which collected all 
of the clinical and pathological variables, including Gleason 
grade, into one prognostic variable.
Epifluorescence microscopy for mGlur I and calcium studies 
in prostate cancer cells
For microscopy studies, the cells were grown on poly(lysine)-
coated chamber glass slides at a density of 40,000 cells per 
chamber. The cells were stained with anti–human PSMA 
antibody (Dako) and the rabbit polyclonal anti–human 
mGluR1/5 antibody (Novus Biologicals). Secondary fluo-
rophore-conjugated antibodies were obtained from Abcam, 
and the nuclear stain Hoechst 33342 was purchased from In-
vitrogen. The slides were first examined on a Nikon Eclipse 
Ti-E fluorescence microscope, followed by imaging on the 
MSK CC’s Molecular Cytology Core Leica SP5 laser-scan-
ning confocal microscope (Leica Microsystems, Inc.). To 
quantify calcium levels, we used the high-throughput Fluo-4 
Direct assay from Invitrogen and the SpectraMax M5 plate 
reader from Molecular Devices. For these studies, cells were 
seeded at a density of 20,000 cells per well on poly(lysine)-
treated black, clear-bottom, 96-well plates (Corning, Inc.), 
followed by overnight growth. Each well’s total volume was 
set at 100 µl, with cells receiving 10 µl of control (1× PBS) 
or treatment solution, after dilution of the stock solutions of 
the various compounds with 1× PBS. Addition of the Fluo-4 
reagent, instrument set, and acquisition parameters were per-
formed in accordance to the assay’s user handbook, which 
was provided by the manufacturer.
Identification of PSMA’s effect on the 
activation of signaling pathways
To determine whether PSMA affects the phosphorylation 
of key kinases, we used the human phosphokinase antibody 
array from R&D Systems, Inc. (ARY003B) and the PathScan 
Akt signaling antibody array kit (9700; Cell Signaling, Inc.). 
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The cells were seeded on poly(lysine)-coated Petri dishes at a 
density of 1,000,000 cells per dish, followed by 24-h growth 
at 37°C, 5% CO2 in complete medium and a 24-h starva-
tion in basal medium. Before the addition of 100 µl control 
(1× PBS) or experimental treatment, cells were supple-
mented with fresh media, as mentioned in the figure legends. 
For compounds whose stock solutions were in DMSO and 
subsequently diluted in 1× PBS, the corresponding control 
cell cohort was treated with 1× PBS that contained equim-
olar concentration of DMSO, with each cohort consisting 
of three replicates. After incubation with the compounds of 
interest, the cells were washed three times with chilled 1× 
PBS, followed by lysis with RIPA buffer (Sigma-Aldrich). 
The cell lysates were processed according to the recommen-
dations of the arrays’ suppliers, and protein concentration was 
determined using the bicinchoninic acid assay (Pierce Bio-
technology). After following the setup and processing steps 
described in each array’s user manual, the arrays were scanned 
and signal was quantified using the near-infrared fluorescence 
Odyssey imaging platform (LI-COR Biosciences, Inc.). 
Changes in phosphorylation were calculated with respect to 
the corresponding untreated control cells, which were cells of 
the same background. Evaluation of a protein’s global phos-
phorylation status was determined via changes in its isoelec-
tric point using the NanoPro 1000 system (Protein Simple) 
and primary rabbit anti–human monoclonal antibodies from 
Cell Signaling. The cells were prepared and treated similarly 
to the phosphorylation array studies, followed by lysis with 
the Bicine/CHA PS buffer (Protein Simple). All reagents and 
supplies, including sample diluent, ampholyte, standards, and 
microcapillaries, were purchased from Protein Simple, with 
the samples prepared according to the guidelines of the in-
strument’s manufacturer, having a protein concentration of 1 
µg/µl and same DMSO content as the ampholyte. Detection 
was achieved through a biotin-conjugated goat anti–rabbit 
secondary antibody and streptavidin-conjugated horseradish 
peroxidase using Compass 2.7.1 software for Windows XP to 
control the instrument and data acquisition and analysis (all 
from Protein Simple). Human inositol 1,4,5-trisphosphate 
levels were quantified with the corresponding Cusabio ELI 
SA kit (Cosmo Bio) according to the supplier’s guidelines, 
using cells grown on Petri dishes followed by cell lysis. The 
SpectraMax M5 microplate reader was used, recording ab-
sorbance at 450 nm with the correction wavelength set at 
600–630 nm. The activation of Akt by PSMA was determined 
with the fluorescent substrate of Akt LS456, which exhibits 
increased fluorescence emission at 700 nm upon phosphor-
ylation by Akt (Shen et al., 2013). LNCaP-Ctrl cells were 
seeded at 10,000 cells per well on poly(lysine)-coated black, 
clear-bottom 96-well plates, and after overnight growth in 
complete media they were administered LS456 ([LS456]fn = 
5 µM), as previously reported. After 24 h at 37°C, 5% CO2, 
the cells were washed three times with warm 1× PBS, sup-
plemented with 100 µl basal medium that was free of serum, 
glutamate and folate for 24 h, and then treated with mono-
glutamate folate ([Glu-fol]fn = 20  µM) and inhibitors ([in-
hibitor]fn = 200 nM) for 2 h at 37°C, 5% CO2, followed by 
fluorescence emission measurements using the Odyssey plat-
form (LI-COR Biosciences).
determination of nitric oxidase synthase activity, and 
quantification of PSA in vitro
The activity of nitric oxidase synthase, which is a downstream 
target of Akt, was evaluated with the nitric oxide synthase 
activity kit (Cayman Chemical), following isolation of the 
cells’ extracellular medium. For this, cells were seeded on 
poly(lysine)-coated Petri dishes at a density of 1,000,000 
cells and grown in the presence of complete medium for at 
37°C, 5% CO2 for 48 h. This was followed by aspiration of 
the media, washing with 1× PBS, and addition of serum-free 
medium and 2-PMPA. The cells were incubated at 37°C, 5% 
CO2, and media were collected at the designated time points, 
followed by sample processing and analysis in line with the 
assay-provided protocol. Similarly, the levels of the PSA were 
determined in the human prostate cancer cell line LNCaP, 
which expresses the AR and has a functional AR cascade. 
The cells were cultivated as mentioned above in this section 
and treated with 2-PMPA for the time indicated in the cor-
responding figures, followed by media isolation and analysis 
with the DEL FIA Prostatus assay (PerkinElmer).
In vitro and in vivo chemotherapy experiments
Cells were seeded at a density of 20,000 cells per well on 
poly(lysine)-coated black, clear-bottom, 96-well plates after 
growth for 24 h in the presence of complete medium at 37°C, 
5% CO2. The medium was then removed, and fresh complete 
medium was added, which was supplemented with the listed 
inhibitors. Control wells were treated with 1× PBS or 1× 
PBS that had equimolar DMSO concentration to correspond 
to the DMSO concentration of inhibitors whose stock solu-
tions were in DMSO and diluted to the desired compound 
concentration with 1× PBS. Viability was determined with 
the Alamar blue assay (Thermo Fisher), after aspirating the 
treatment medium and addition of 10% Alamar blue–con-
taining fresh medium, and incubation for 3 h at 37°C, 5% 
CO2. Inhibition of PSMA with 2-PMPA in LNCaP-Ctrl 
cells had comparable results with a previous report that used 
LNCaP cells (Yao and Bacich, 2006). Animal studies were 
conducted with adult, male, athymic, nude mice obtained 
from Harlan Laboratories. All animal studies were conducted 
in accordance to MSK CC’s Institutional Animal Care and 
Use Committee, with procedures approved by MSK CC’s 
Research Animal Resource Center. For the experiment with 
animals bearing LL2-derived tumors, adult male PSMA−/− 
C57BL/6J mice were obtained from MSK CC’s internal 
small-animal colony. Xenograft engraftment was achieved by 
subcutaneous injection of 1,000,000 cells in 100 µl Matri-
gel on each flank, unless otherwise stated. All compounds 
were administered i.v. (100 µl), with control cohorts treated 
with vehicle (1× PBS or 1× PBS with equimolar DMSO 
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concentration for compounds whose stocks were in DMSO 
and then diluted to the desired concentration with 1× PBS; 
DMSO content was less than 2%). Tumor measurements were 
taken with calipers, and the animals were anesthetized with 
isoflurane whenever needed. They were euthanized once the 
tumor reached a diameter of 10 mm, in accordance with in-
stitutional policies (maximum tumor volume allowed by In-
stitutional Animal Care and Use Committee was 524 mm3). 
Control animals with LNCaP-Ctrl xenografts had established 
tumors ∼3 wk after xenograft implantation, and the tumors 
reached the maximum allowable volume within 3 to 4 wk. 
Drug dosages were based on the compounds’ characteris-
tics and to prevent any side effects. For instance, 2-PMPA, 
which is very hydrophilic and rapidly cleared from the body, 
was administered at higher concentration than enzalutamide, 
which is hydrophobic, has 98% protein binding, and has a 
biological half-life of 9 d. To examine whether PSMA plays 
a role in early tumor establishment and development, ani-
mals were treated with 2-PMPA immediately after xenograft 
implantation. Imaging studies were conducted at MSK CC’s 
Small Animal Imaging Core facilities using the IVIS Spec-
trum system (PerkinElmer).
Immunohistochemical examination of xenografts and 
prostate cancer patient–derived tissue microarray
Human prostate cancer xenografts that were established in 
adult, male, athymic, nude mice were collected after the an-
imals were euthanized, followed by the excised tumors fix-
ation in 10% neutral-buffered formalin for 48 h. They were 
then grossed and embedded in paraffin, followed by section-
ing to 4 µm onto charged glass slides in the MSK CC Mo-
lecular Cytology Core. Immunohistochemical staining and 
processing was done at HistoWiz, Inc. using human anti–
PSMA antibody from Dako and human anti–pAkt1 and pan-
Akt antibodies from Cell Signaling. The slides were imaged 
using the Zeiss MIR AX MIDI slide scanner and Pannoramic 
Viewer software (3DHistech Ltd.), whereas quantification of 
immunohistochemistry signal intensity was done with ImageJ 
after normalization to object count. The tumor tissue micro-
array was generated from localized prostate cancer specimens 
obtained from the MSK CC Urology Service, and informed 
consent was obtained from all subjects. Approval was obtained 
from the institutional review board and the Human Tissue 
Utilization Committee before study of human specimens. 
Immunostaining was done with the human anti–PSMA 
antibody from Dako and human anti–phospho-4EBP1 and 
anti–PTEN antibodies from Cell Signaling at the MSK 
CC Pathology Department.
PEt/MrI acquisition
Images were obtained after intravenous injection of 68Ga-
HBED-CC constituting an extracellular PSMA ligand 
synthesized as described previously (Martin et al., 2014). Si-
multaneous PET/MRI was performed using an integrated 
whole-body PET/MRI system (Siemens Biograph mMR; 
Siemens Healthcare), with mpMR-examination that in-
cluded T2w, DWI, and DCE of the prostate being performed 
simultaneously during a 15-min PET scan. A workflow chart 
of this protocol and details for PET-data reconstruction, in-
cluding the use of the T1w VIBE Dixon for attenuation cor-
rection, have been published previously (Souvatzoglou et al., 
2013). All reported investigations were conducted in accor-
dance with the Declaration of Helsinki as well as national 
regulations. Consent to publish photos was obtained from 
all patients. The retrospective data analysis was approved by 
the ethics committee of the Technical University of Munich, 
Germany (permit 5665/13).
Epifluorescence microscopy of histology slides of biopsies 
from prostate cancer patients imaged with PEt/MrI
For further analysis and to obtain additional molecular in-
formation, representative tissue sections containing localized 
prostate cancer were prepared from each radical prostatec-
tomy of the patients undergoing PET/MRI at the Technical 
University of Munich, Germany. Samples were fixed in 10% 
neutral-buffered formalin for 48 h, grossed, and embedded in 
paraffin before sectioning to 4 µm onto charged glass slides. 
The slides were deparaffinized as follows: twice in xylene for 
5 min each, followed by twice in 100% ethanol for 5 min 
each, followed by twice in 95% ethanol in water for 5 min 
each and briefly in pure water. Two slides each from nearly 
all cases were then immediately probed with a solution con-
taining 10% FBS (Gibco) in anti–PSMA antibody (1× 3E6, 
M3620; Dako) and either anti-pAKT(S473) (4060S, 1:83; 
Cell Signaling Technologies) or anti-pAKT(T308) (D25E6, 
1:83, Cell Signaling Technologies) antibody for 1 h at room 
temperature. The slides were then washed twice for 5 min 
each with 1× PBS and then probed with goat anti-mouse 
secondary antibody-fluorescein conjugate (ab97022, 1:250; 
Abcam) with chicken anti–rabbit secondary antibody conju-
gated to Alexa Fluor 647 (A21443, 1:250; Invitrogen) in 1× 
PBS for 30 min at room temperature. After aspiration of the 
secondary antibody solution, the slides were then exposed to 
Hoechst 33342 dye for 1.5 min (H3570, 1:1,000 in 1× PBS; 
Invitrogen). The slides were then washed twice more with 
1× PBS for 5 min each before adding mounting medium 
(Dako Faramount Aqueous Mounting Medium) and a glass 
coverslip. The slides were then immediately viewed using 
a Nikon 80i upright epifluorescence microscope equipped 
with a Nikon DS-Qi1Mc dark-field CCD camera and ex-
cited by a Nikon Intensilight C-HGFI lamp. All images were 
recorded and processed using Nikon Imaging Software Ele-
ments, which was also used for signal quantitation.
Statistics
All data are presented as mean ± SEM unless otherwise 
stated. P-values were derived from two-tailed Student’s t 
tests using the Shapiro–Wilk tests for normally distrib-
uted data, the Mann–Whitney U tests for nonnormally 
distributed data, or ANO VA (GraphPad Prism; Graph-
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Pad Software, Inc.), with the data meeting appropriate 
test assumptions. For animal studies determining whether 
monotherapy to inhibit PSMA’s enzymatic activity confers 
a therapeutic advantage, a priori power analysis identified 
that the probability is 85% that the study will detect a treat-
ment difference at a two-sided 0.05 significance level, for 
a sample size of four per independent study group, if the 
control group experiences tumor growth greater than or 
equal to 50% from the time treatment commences, where 
the treatment group experiences tumor stasis or reduction. 
No animals were excluded, and treatment randomization 
was applied. Blinding was used, where animals were coded 
and treatment and tumor measurement did not occur at the 
same time. No a priori analysis was used to predetermine 
the animal sample size in combination therapy or nanoth-
erapeutic in vivo studies and evaluation of clinical data. 
For the tissue microarray and PET-based studies, analyses 
were performed using the PLS_Toolbox v. 8.0 (Eigenvec-
tor Research, Inc.). Specifically for the tissue microarray, 
the data from 76 patients with localized prostate cancer 
(PSMA level, PSMA purity, 4EBP1 phosphorylation, and 
Gleason score) were initially normalized to zero mean and 
unit variance. A PCA model was generated, with the first 
two principal components capturing 62.5% of the dataset 
variance. One patient sample was excluded as an outlier. 
Based on the principal components, Ward’s method was 
used for clustering the patients, and a dendrogram was cre-
ated using the Mahalanobis distance. For the patients im-
aged with PET/MRI using the PSMA-specific PET agent, 
the samples were separated in two groups based on whether 
the corresponding histology slides were screened for phos-
phorylation of Akt at S473 (51 samples from 11 out of 12 
patients) or at T308 (72 samples from 12 out of 12 patients), 
and two PCA models were developed. Additional variables 
included in the models were the expression levels of PSMA 
and PSA (low, medium, and high), the Gleason score, and the 
standardized uptake values from PET (SUV and SUVmean). 
The biplots, which show the relations of the categorical 
variables as well as the distribution of the patient sam-
ples, are presented, as well as the principal components 
derived from the analysis.
online supplemental material
Fig. S1 shows that PSMA expression is up-regulated in cancer. 
Fig. S2 shows that enzymatically active PSMA is required to 
activate p110b-dependent downstream signaling. Fig. S3 shows 
that PSMA processes glutamated folates in prostate cancer 
and that the released glutamate activates mGluR I. Fig. S4 
shows that PSMA activates the PI3K–Akt axis in vitro and 
in prostate cancer patients. Fig. S5 shows in vivo evaluation 
of the inhibition of PSMA as a potential therapy in prostate 
cancer. Table S1 shows expression of PSMA associates with 
biochemical recurrence in prostate cancer patients. Table 
S2 shows expression of PSMA associates with metastasis in 
prostate cancer patients.
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Figure S1. PSMA expression is up-regulated in cancer. (A) Immunoblot of the human prostate cancer cell lines used in the present work (rhPSMA, 
recombinant human PSMA). (B) Quantitative real-time PCR to assess expression of PSMA. LNCaP-Ctrl cells were treated with the PSMA inhibitor 2-PMPA for 
48 h (n = 3 per group). Graph shows mean ± SEM. ns, not significant; ***, P < 0.001; ****, P < 0.0001 (ordinary one-way ANO VA). Table lists the graph’s data of 
relative PSMA expression, where LNCaP-Ctrl PSMA expression served as the calibrator for all samples. (C) Immunoblot analysis for prostate cancer cells ex-
pressing or lacking PSMA (PSMAmut, express an enzymatically inactive form of PSMA; PC3-PSMAwt_H, express high levels of wild-type PSMA; PC3-PSMAwt_L, 
express low levels of wild-type PSMA). (D–G) Quantification of immunohistochemistry images from mouse xenografts. Signal intensity analysis of slides 
from PC3-Ctrl and PC3-PSMA tumors grown in athymic nude mice and stained with the corresponding human antibodies. Intensity was measured using 
the ImageJ software (nPC3-Ctrl_anti-PSMA = nPC3-Ctrl_anti-pan-AKT = 10; nPC3-Ctrl_anti-pAKT1 = nPC3-PSMA_anti-PSMA = nPC3-PSMA_anti-pan-AKT = nPC3-PSMA_anti-pAKT1 = 15). (G) Ratio of 
phospho-AKT1 intensity (IpAKT1) over the mean of the total AKT staining intensity (IpanAKT) for each group’s slides. Graphs show mean ± SD. ns, not significant; 
***, P < 0.001; ****, P < 0.0001 (unpaired t test).
S21JEM
Figure S2. Enzymatically active PSMA is required to activate p110b-dependent downstream signaling. (A) Inhibition of PI3K’s catalytic subunits 
differentially affects Akt’s phosphorylation. LNCaP-Ctrl cells were grown in complete medium and treated for 2 h with the corresponding inhibitor. Control 
cells were treated with 1× PBS. Changes in Akt’s phosphorylation were determined with the NanoPro system (n = 3 per treatment). Graph shows mean ± 
SEM. **, P < 0.01; ***, P < 0.001 (ordinary one-way ANO VA). (B) Addition of monoglutamate folate (Glu-Fol) did not affect Akt’s phosphorylation in LNCaP 
cells lacking PSMA (LNCaP-KD). Cells were starved for 24 h and then supplemented with basal medium and different concentrations of Glu-Fol (+ = 
15 µM; ++ = 30 µM), followed by NanoPro analysis (n = 3 per treatment). Graph shows mean ± SEM. (C–E) PC3-PSMA cells were starved for 24 h in basal 
medium, followed by 2 h stimulation (mut, mutant PSMA unable to process glutamate folate; wt, enzymatically active wild-type PSMA). Phosphorylation 
was determined with the NanoPro system. *, P < 0.05; ***, P < 0.001. (F–K) PSMA regulates Akt phosphorylation regardless of the presence of PTEN (22Rv1: 
PTEN-positive; LNCaP: PTEN-deficient). The cells were starved for 24 h and then treated with Glu-Fol and the mTORC1/2 inhibitor (INK 128) for 2 h. Changes 
in phosphorylation were determined with the NanoPro platform (n = 3 per treatment). Graphs show mean ± SEM. ns, not significant; *, P < 0.05; **, P < 0.01 
(unpaired t test). (L) Nitric oxide levels were measured with the nitric oxide synthase activity assay, because this enzyme is activated by Akt. LNCaP-Ctrl cells 
were treated with 2-PMPA for the time indicated (n = 8 per treatment). (M) PSMA, through activation of the PI3K–Akt signaling cascade, down-regulates the 
androgen receptor pathway. The activity of the androgen receptor pathway, reflected in production of PSA, was determined in LNCaP-Ctrl cells cultivated 
in complete medium and treated with 2-PMPA (n = 6 per treatment) using the DEL FIA Prostatus assay. Graphs show mean ± SEM. ns, not significant; *, P < 
0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 (ordinary one-way ANO VA).
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Figure S3. PSMA processes glutamated folates in prostate cancer, and the released glutamate activates mGlur I. (A) Increase in cytoplasmic 
calcium levels in LNCaP-Ctrl cells in response to addition of monoglutamated folate (Glu-Fol; vehicle: 1× PBS). Before treatment with Glu-Fol, the cells were 
incubated in basal-RPMI medium that was free of serum, folate, and glutamate for 4 h at 37°C, 5% CO2. Detection was achieved with the Fluo-4 Direct 
calcium kit. (B and C) Mono- and polyglutamate folates affect calcium levels in PSMA-expressing LNCaP-Ctrl prostate cancer cells grown in complete (B) 
and basal (free of serum, glutamate and folate) medium (C; n = 8; Glu-Fol, monoglutamate folate; Glu3-Fol, triglutamate folate; Glu5-Fol, pentaglutamate 
folate). (D and E) Changes in cytoplasmic calcium levels of LNCaP-Ctrl cells in the presence of monoglutamated folate, 2-PMPA (PSMA inhibitor), and an 
agonist (l-quisqualic acid) or antagonist (L-AP3) of the glutamatergic system in complete medium (n = 8 per condition). The inset in D shows a representa-
tive wide-view immunofluorescence microscopy image of fixed LnCaP-Ctrl cells stained with the monoclonal mouse anti–human PSMA antibody, polyclonal 
rabbit anti–human mGluR1/5 antibody, and Hoechst 33342. (F) Activation of mGluR I by its agonist (S)-3,5,-DHPG mobilizes calcium to the cytoplasm of 
prostate cancer cells. (n = 8 per condition). The cells were in complete medium, and differences were calculated based on calcium levels of the correspond-
ing untreated cells. (G) Quantification of cytoplasmic calcium levels in cells expressing (LNCaP-Ctrl and PC3-PSMA) or lacking PSMA and (LNCaP-KD and 
PC3-Ctrl) in complete medium, through the Fluo-4 Direct assay. (H) Inositol trisphosphate (IP3) levels in prostate cancer cells grown in complete medium 
and treated for 2 h with the PSMA inhibitor 2-PMPA. Changes in [IP3] were calculated with respect to the corresponding cell line grown in complete medium 
without the inhibitor (n = 12 per condition). (I) Confocal laser scanning microscopy on fixed LNCaP-Ctrl cells stained with the antibodies listed above for 
panel D's inset shows colocalization of mGluR1/5 and PSMA. Representative image of 20 scans is shown. Bar, 10 µm. (J) Evaluation of PSMA’s ability to pro-
cess monoglutamate folate and release free glutamate, determined through the Amplex Red Glutamic Acid assay. Cells were deprived of serum, glutamate, 
and folate for 4 h before treatment (PC3-PSMAwt: expressing wild-type PSMA; PC3-PSMAmut: expressing enzymatically inactive PSMA; n = 8 per condition). 
Graphs show mean ± SEM. ns, not significant; *, P < 0.05, **, P < 0.01, ***, P < 0.001; ****, P < 0.0001 (ordinary one-way ANO VA).
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Figure S4. PSMA activates the PI3K–Akt axis in vitro and in prostate cancer patients. (A and B) Inhibition of PSMA improves response to chemo-
therapy. Suppression of PSMA’s enzymatic activity improves the cytotoxic activity of mTOR inhibitors (everolimus and AZD8055) and XL184 (VEG FR2 and 
multikinase inhibitor). The cells were treated with these agents ([drug] = 200 nM) and 2-PMPA (200 nM) for 48 h at 37°C, 5% CO2 (n = 12 per treatment). 
Graphs show mean ± SEM. *, P < 0.05, **, P < 0.01; ****, P < 0.0001 (ordinary one-way ANO VA). (C–F) Expression of PSMA is associated with phosphorylation 
of the Akt target 4EBP1 in prostate cancer patients. Patient samples in a tissue microarray analyzed by PCA demonstrate that elevated phosphorylation of 
the Akt-target 4EBP1 is associated with increased PSMA expression in prostate cancer with the majority of the data variance captured along the two pri-
mary principal components (PC1 and PC2). Scores of tissue microarray patient samples used for the PCA model of Fig. 7 A. The same data are plotted three 
times color-coded for the expression of PSMA, 4EBP1, and PTEN, respectively. (G and H) Representative immunohistochemistry images of patient samples 
corresponding to the clusters of Fig. 7 A.
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Figure S5. In vivo evaluation of the inhibition of PSMA as a potential therapy in prostate cancer. (A–I) The expression of PSMA can be assessed 
with specific small-molecule probes. Near-infrared fluorescent images of PC3-Ctrl and PC3-PSMA xenografts with the fluorescent PSMA-targeting agent 
YC-27 accumulating at the PSMA-expressing tumor (1 nM YC-27IV); images were acquired at 10 min, 1 h, 3 h, 5 h, and 24 h. After 24 h, the mouse was sac-
rificed, and tumors, muscle, liver, spleen, kidneys, and intestine were imaged. All images were acquired on a Pearl Impulse Imager (LI-COR Biosciences, Inc.). 
(H and I) Expression of PSMA was also determined in vivo using the PSMA tracer [18F]DCFPyL and positron emission tomography (PET). A male NOD-SCID 
mouse implanted with PC3-Ctrl and PC3-PSMA xenografts was administered 200 µCi (7.4 MBq) of [18F]DCFPyL i.v. in 200 µl of 1× PBS. Images were ac-
quired with an eXplore VIS TA small animal PET scanner (GE Healthcare) at 10 and 60 min. The dwell time at each bed position was 10 min for a total scan 
time of 20 min. An energy window of 250–700 keV was used. Images were reconstructed using the FORE/2D-OSEM method (2 iterations, 16 subsets) and 
included correction for radioactive decay, scanner dead time, and scattered radiation. (J–P) The expression of PSMA by the neoplastic lesion affects tumor 
growth. (J) Survival plots of male, athymic nude mice with bilateral human prostate cancer xenografts on their flanks (n = 5 animals per cohort). The mice 
with LNCaP-Ctrl tumors received daily i.v. treatment, upon tumor implantation (vehicle: 1× PBS; 2-PMPA [L]: 20 mg/kg; 2-PMPA [H]: 40 mg/kg). *, P < 0.05; 
**, P < 0.01; ****, P < 0.0001 (log-rank [Mantel-Cox] test). (K–M) Mice with bilateral LNCaP-KD xenografts on their flanks developed small tumors, which grew 
slowly and resulted in improved survival. The animals were treated with either vehicle (1× PBS) or 40 mg/kg 2-PMPA administered i.v. daily upon xenograft 
implantation (nVehicle = n2-PMPA = 5 mice; black arrow indicates the day of xenograft implantation, purple arrow the day treatment started, purple line the 
length of treatment, and continuous blue line that the treatment was daily). Graphs in L show mean ± SEM. ns, not significant (unpaired t test). P-value 
in K was determined using the Gehan–Breslow–Wilcoxon test. (N) Waterfall plot of animals having single LNCaP-Ctrl xenografts on their flank (nNPS = 4; 
nEnzalutamide + NPS = 6; NPS: mGluR group I antagonist NP S2390). Treatment was administered daily i.v. on day 24 after xenograft implantation (NPS: 1 mg/
kg; enzalutamide + NPS: 0.5 mg/kg enzalutamide and 1 mg/kg NPS). Inset shows a comparison between therapy with 2-PMPA (2-P) alone and 2-PMPA and 
enzalutamide (E + 2-P). The graph depicts the corresponding data of Fig. 6 D, showing mean ± SEM. *, P < 0.05 (unpaired t test). (O) Inhibition of PSMA’s 
carboxypeptidase activity with 2-PMPA impairs tumor growth in PSMA-expressing xenografts. Mice with either bilateral LNCaP-Ctrl or PC3-Ctrl xenografts 
on both of their flanks were treated daily with vehicle (1× PBS) or PSMA inhibitor (20 mg/kg 2-PMPA) administered i.v. immediately after implantation of 
the cells (n = 3 mice per cohort). Graph shows mean ± SEM. ns, not significant; ***, P < 0.001 (ordinary one-way ANO VA). (P) Treatment with 2-PMPA does 
not impair tumor development in PSMA-null mice (C57BL/6J) implanted with Lewis lung carcinoma LL2 xenografts on their flank (nvehicle = 4; n2-PMPA = 6). 
Vehicle (1× PBS) and 20 mg/kg 2-PMPA were administered daily i.v. immediately after the xenografts were implanted. Graph shows mean ± SEM. ns, not 
significant (unpaired t test).
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Table S1. Expression of PSMA associates with biochemical recurrence in prostate cancer patients
Variables in the equation P HR 95% CI for HR
Lower Upper
PSMA expression Z >2 0.039 2.658 1.049 6.739
Biostats_nomogram_Stephanson 0 0.961 0.947 0.974
Multivariate Cox regression (MSK CC prostate cancer patient cohort, PMID 25024180) of the correlation between PSMA expression and prostate cancer recurrence. BCR, biochemical recur-
rence; CI, confidence interval; HR, hazard ratio.
Table S2. Expression of PSMA associates with metastasis in prostate cancer patients
Variables in the equation P HR 95% CI for HR
Lower Upper
PSMA expression Z >2 0.019 3.949 1.248 12.501
Biostats_nomogram_Stephanson 0 0.963 0.945 0.981
Multivariate Cox regression of association between PSMA expression and metastasis (MSK CC prostate cancer patient cohort PMID 25024180). CI, confidence interval; HR, hazard ratio.
